Trifecta Capital Advisors, LLC Bristol Myers Squibb CO Transaction History
Trifecta Capital Advisors, LLC
- $452 Billion
- Q2 2024
A detailed history of Trifecta Capital Advisors, LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Trifecta Capital Advisors, LLC holds 59 shares of BMY stock, worth $2,915. This represents 0.0% of its overall portfolio holdings.
Number of Shares
59
Previous 59
-0.0%
Holding current value
$2,915
Previous $3.2 Million
23.41%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding BMY
# of Institutions
2,400Shares Held
1.5BCall Options Held
29.7MPut Options Held
32.2M-
Vanguard Group Inc Valley Forge, PA187MShares$9.22 Billion0.15% of portfolio
-
Black Rock Inc. New York, NY159MShares$7.84 Billion0.15% of portfolio
-
State Street Corp Boston, MA91.4MShares$4.52 Billion0.17% of portfolio
-
Jpmorgan Chase & CO New York, NY74.6MShares$3.69 Billion0.27% of portfolio
-
Charles Schwab Investment Management Inc San Francisco, CA59.1MShares$2.92 Billion0.47% of portfolio
About BRISTOL MYERS SQUIBB CO
- Ticker BMY
- Exchange NYSE
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 2,126,160,000
- Market Cap $105B
- Description
- Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...